George Gould joins BioSpecifics board
This article was originally published in Scrip
BioSpecifics Technologies, a biopharmaceutical company developing first-in-class collagenase-based products, has elected George Gould, an attorney, to its board of directors. Mr Gould is principal of George M. Gould, LLC, and of counsel to Gibbons PC. He has expertise in pharmaceutical and biotechnology intellectual property law, and was notably vice-president of licensing and corporate development and chief patent counsel at Roche for 28 years.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.